Joseph M Unger
#173,956
Most Influential Person Now
Researcher
Joseph M Unger's AcademicInfluence.com Rankings
Joseph M Ungerengineering Degrees
Engineering
#7954
World Rank
#9406
Historical Rank
Electrical Engineering
#2480
World Rank
#2599
Historical Rank
Joseph M Ungercomputer-science Degrees
Computer Science
#10737
World Rank
#11294
Historical Rank
Computational Linguistics
#2703
World Rank
#2732
Historical Rank
Machine Learning
#4895
World Rank
#4952
Historical Rank
Artificial Intelligence
#5264
World Rank
#5335
Historical Rank
Download Badge
Engineering Computer Science
Joseph M Unger's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Joseph M Unger Influential?
(Suggest an Edit or Addition)Joseph M Unger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Underrepresentation of patients 65 years of age or older in cancer-treatment trials. (1999) (2101)
- Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. (2009) (436)
- Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. (2015) (424)
- New treatment options have changed the survival of patients with follicular lymphoma. (2005) (378)
- Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. (2004) (317)
- Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. (2006) (286)
- Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. (2013) (283)
- The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. (2016) (256)
- Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. (2008) (252)
- Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. (2019) (227)
- Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. (2018) (213)
- Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation (2019) (213)
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. (2002) (210)
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. (2002) (202)
- Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. (2009) (201)
- Patient income level and cancer clinical trial participation. (2013) (193)
- Comparison of survival outcomes among cancer patients treated in and out of clinical trials. (2014) (185)
- Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial (2018) (179)
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. (2013) (170)
- A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. (2003) (162)
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. (2008) (156)
- Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. (2008) (149)
- Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. (2016) (144)
- Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. (2001) (138)
- Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. (2013) (137)
- A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. (2013) (124)
- Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. (2009) (116)
- Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials (2016) (111)
- Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. (2002) (111)
- Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. (2006) (109)
- The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. (2001) (108)
- A phase 2 trial of complete resection for stage IV melanoma (2011) (105)
- The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. (2016) (104)
- Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation (2019) (101)
- Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. (2016) (101)
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 (2009) (96)
- Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma (2010) (90)
- A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). (2012) (88)
- Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials (2018) (87)
- Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. (2000) (87)
- Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). (2019) (86)
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. (2016) (79)
- Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma (2013) (77)
- Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. (2008) (76)
- Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. (2005) (75)
- Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. (2015) (72)
- “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials (2020) (71)
- Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. (2020) (70)
- Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. (2007) (67)
- A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma. (2007) (63)
- Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials (2020) (63)
- Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. (1998) (59)
- Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. (2018) (58)
- A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. (2012) (58)
- Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. (2017) (57)
- Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices (2019) (57)
- The impact of the COVID-19 pandemic on health services utilization in China: Time-series analyses for 2016–2020 (2021) (55)
- Cross‐Sectional Versus Longitudinal Estimates of Cognitive Change in Nondemented Older People: A CERAD Study (1999) (55)
- Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma (2007) (54)
- The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. (2003) (54)
- Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715) (2018) (52)
- Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (2011) (51)
- Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. (1998) (50)
- Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. (2018) (49)
- Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials (2007) (49)
- Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study (1998) (48)
- The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. (2016) (43)
- Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 (2005) (42)
- Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). (2004) (41)
- Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies (2020) (38)
- HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence (2018) (38)
- Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. (2020) (37)
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. (2016) (36)
- Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials (2001) (35)
- Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials (2021) (34)
- Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. (2001) (33)
- How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? (2017) (33)
- A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab (2013) (33)
- Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). (2014) (32)
- The COVID-19 pandemic and new clinical trial activations (2021) (30)
- Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials (2022) (30)
- Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer (2021) (29)
- Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials (2020) (29)
- Supplement use during an intergroup clinical trial for breast cancer (S0221) (2013) (28)
- Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. (2001) (27)
- Ovarian protection during adjuvant chemotherapy. (2015) (27)
- Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) (2018) (27)
- R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433 (2014) (27)
- A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 (2003) (25)
- Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study (2017) (24)
- The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population (2017) (23)
- Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. (1997) (23)
- Estimated impact of the Prostate Cancer Prevention Trial on population mortality (2005) (23)
- Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings (2020) (23)
- Capacity to Provide Geriatric Specialty Care for Older Adults in Community Oncology Practices. (2020) (22)
- Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial (2018) (21)
- The diffusion of docetaxel in patients with metastatic prostate cancer. (2015) (21)
- Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups (2019) (20)
- Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. (2017) (19)
- Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWO (2006) (19)
- The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. (2019) (19)
- A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma (2011) (18)
- Association of National Cancer Institute–Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications (2019) (18)
- Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic (2021) (17)
- Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. (2015) (17)
- Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. (2020) (17)
- The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity (2019) (16)
- Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) (2008) (15)
- Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800). (2004) (14)
- Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era (2020) (14)
- Association between body mass index and response to duloxetine for aromatase inhibitor‐associated musculoskeletal symptoms in SWOG S1202 (2019) (14)
- The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. (2004) (13)
- Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. (2004) (13)
- Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. (2015) (12)
- Religiosity, Social Support, and Ethnic Identity: Exploring “Resilience Resources” for African-American Women Experiencing HIV-Related Stigma (2019) (12)
- Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. (2021) (11)
- Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. (2021) (11)
- What Keeps Patients Out of Clinical Trials? (2020) (11)
- Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. (2020) (10)
- An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. (2005) (10)
- Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial (1999) (10)
- Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. (2003) (10)
- Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. (2012) (10)
- Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program (2020) (10)
- Summary report of the Altaic panel (1990) (10)
- Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (2018) (9)
- Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 (2004) (9)
- Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. (2016) (9)
- Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State. (2019) (9)
- Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) (2018) (9)
- Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events (2020) (9)
- Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. (2019) (9)
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival (2014) (8)
- Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients. (2018) (8)
- Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515 (2010) (8)
- Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV. (2019) (8)
- A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma (2011) (8)
- A randomized phase III double-blind clinical trial (S1600) evaluating the effect of immune-enhancing nutrition on radical cystectomy outcomes. (2018) (7)
- Abstract GS4-04: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200) (2018) (7)
- Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. (2019) (7)
- Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study (2004) (7)
- Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105. (2019) (7)
- Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials (2020) (7)
- Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. (2019) (7)
- Adolescent and young adult enrollment to a National Cancer Institute–sponsored National Clinical Trials Network Research Group over 25 years (2021) (6)
- R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 (2010) (6)
- Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials (2018) (6)
- The Effect of the SARS-CoV-2 Pandemic on Health Services Utilization in China: Time-Series Analyses for 2016-2020 (2021) (6)
- Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221) (2018) (5)
- Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927). (2014) (5)
- Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. (2021) (5)
- SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. (2012) (5)
- Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials. (2018) (5)
- S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. (2022) (5)
- Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials (2020) (5)
- Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer. (2020) (5)
- Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors. (2021) (5)
- Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. (2019) (5)
- Estimating global treatment toxicity burden from adverse‐event data (2018) (5)
- Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer. (2021) (5)
- Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (2016) (5)
- Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202) (2017) (5)
- Feasibility and Validity of Asking Patients to Define Individual Levels of Meaningful Change on Patient-Reported Outcomes. (2020) (5)
- Hepatitis B Birth Dose: First Shot at Timely Early Childhood Vaccination. (2019) (5)
- Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. (2021) (4)
- Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence. (2018) (4)
- The role of myeloablation for lymphoma. (2014) (4)
- Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization. (2019) (4)
- Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis. (2004) (4)
- Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims (2019) (4)
- Caregiver engagement practices in National Cancer Institute Clinical Oncology Research Program settings: Implications for research to advance the field (2020) (3)
- Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD. (2020) (3)
- Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC). (2019) (3)
- Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702 (2017) (3)
- Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials. (2019) (3)
- Using patient-reported outcomes in measurement-based care: perceived barriers and benefits in oncologists and mental health providers (2021) (3)
- Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer-Reply. (2016) (3)
- The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. (2017) (3)
- A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study (2002) (3)
- Symptom clusters in patients with advanced prostate cancer. (2015) (3)
- Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008) (2018) (3)
- A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events (2019) (2)
- Patterns of Scientific and Clinical Impact in Cancer Randomized Clinical Trials (2022) (2)
- Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy (2001) (2)
- Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS) (2018) (2)
- Female representation in clinical trials leading to FDA cancer drug approvals for gastrointestinal (GI) cancers between 2008 to 2018. (2020) (2)
- Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology-Reply: Beyond Citation Counts. (2016) (2)
- Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (2014) (2)
- Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials (2021) (2)
- Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials. (2020) (2)
- Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib (2017) (2)
- Cancer Care During COVID-19-A Shock to the System. (2022) (2)
- ‘Minority report’: how best to analyze clinical trial data to address disparities (2009) (2)
- A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202. (2014) (2)
- Transdisciplinary research outcomes based on the Transdisciplinary Research on Energetics and Cancer II initiative experience. (2020) (2)
- Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials (2022) (2)
- Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208 (2017) (2)
- Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105). (2020) (2)
- Outcome of African American Women with Breast Cancer in Cooperative Group Clinical Trials (2006) (2)
- Tailoring Pain Interference Measurement in People with Cancer: A Feasibility Study. (2022) (2)
- A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. (2012) (2)
- Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer. (2015) (2)
- Reply to M.C. Chamberlain (2009) (2)
- Cumulative incidence of financial hardship in metastatic colorectal cancer (mCRC) patients (pts): Primary endpoint results for SWOG S1417CD. (2020) (2)
- Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients (2016) (2)
- The Influence of Older Age on Physician and Patient Decision-Making Regarding Enrollment to Breast Cancer Clinical Trials. (2009) (1)
- Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204. (2018) (1)
- “When offered to participate”: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. (2020) (1)
- Patient comorbid conditions and cancer clinical trial participation. (2018) (1)
- Inequitable access to surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer (2020) (1)
- The impact of positive SWOG treatment trials on population survival. (2017) (1)
- Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. (2022) (1)
- History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. (2017) (1)
- Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then Trust. (2019) (1)
- Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. (2007) (1)
- Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors (2021) (1)
- Abstract PD6-10: Association between adherence to cardiovascular medications and cardiovascular events following a diagnosis of early stage breast cancer (2019) (1)
- Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008). (2015) (1)
- Common methods of determining meaningful change in clinical practice: implications for precision patient-reported outcomes (2022) (1)
- A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013 (2020) (1)
- Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC). (2019) (1)
- Abstract 4344: Racial representativeness of cancer clinical trials sponsored by the National Cancer Institute compared to pharmaceutical companies (2020) (1)
- Markers of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab. (2013) (1)
- An Editorial on Tailoring Patient-Reported Outcomes to the Individual Patient: Precision PROs (2020) (1)
- Accrual patterns of the Southwest Oncology Group (SWOG) by sex, race/ethnicity, and age: Updated and expanded analyses. (2004) (1)
- Reimbursing Patients for Participation in Cancer Clinical Trials. (2019) (1)
- Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. (2020) (1)
- Diffusion of abiraterone use in prostate cancer patients. (2016) (0)
- P35-M Quantitative Measurement of Gene Expression from Formalin-Fixed Tissue Providing Identical Results as Fresh Tissue: Biomarker Validation using Clinical Samples (2007) (0)
- Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials. (2016) (0)
- Lost in Translation: Participation in Cancer Clinical Trials for Patients With Limited English Proficiency. (2023) (0)
- Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. (2023) (0)
- Erratum: 'Chemoprevention of prostate cancer with finasteride, an intergroup trial' (Annals of Oncology (1994) 5 (Suppl 8) 65 (P324)) (1995) (0)
- Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). (2018) (0)
- Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715). (2017) (0)
- Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial ( SWOG S 0421 ) (2018) (0)
- Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey (2022) (0)
- Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors (2021) (0)
- OT2-07-02: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer. (2011) (0)
- Central Nervous System (CNS) Relapse in Agressive Non-Hodgkin’s Lymphoma; Does CNS Prophylaxis Work?. (2007) (0)
- Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms (2018) (0)
- Comparison of cancer incidence to available oncology clinical trial slots. (2018) (0)
- Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200). (2021) (0)
- Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain (2022) (0)
- Socioeconomic deprivation and patient-reported outcomes in symptom management trials for patients with breast cancer. (2022) (0)
- A Risk Prediction Model to Identify Newborns at Risk for Missing Early Childhood Vaccinations. (2021) (0)
- Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2021) (0)
- Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies (2022) (0)
- Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). (2021) (0)
- Abstract SY43-03: Sex differences in severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in Cancer clinical trials: An evidentiary perspective (2023) (0)
- Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204 (2022) (0)
- Racial and Ethnic Disparity in Preference-Weighted Quality of Life: Findings from the Selenium and Vitamin E Cancer Prevention Trial. (2023) (0)
- Representativeness, Generalizability, and Diffusion of Cancer Clinical Trial Treatments (2013) (0)
- Abstract A058: Patient and neighborhood factors associated with receipt of surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer (2020) (0)
- Abstract 4681: Effect of physician recommendation on multivitamin and antioxidant supplement use during chemotherapy in an adjuvant trial for breast cancer (SWOG S0221) (2011) (0)
- Abstract PD12-03: Predictors of pain reduction in trials of interventions for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) (2021) (0)
- Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials. (2020) (0)
- A comparison of oncologist versus mental health provider attitudes towards standardized and tailored patient-reported outcomes (2021) (0)
- Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials. (2021) (0)
- Trends in obesity among patients registered to SWOG cancer clinical treatment trials. (2020) (0)
- Abstract C006: Sociodemographic predictors of adherence to postoperative surveillance colonoscopy among patients diagnosed with nonmetastatic colorectal cancer (2020) (0)
- The Use of Superlatives in Cancer Research (2016) (0)
- Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials. (2017) (0)
- Abstract PD8-06: Incidence of Acute and Persistent Clinically Meaningful Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481) (2023) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- 1503O Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials (2021) (0)
- Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221 (2016) (0)
- Feasibility of a digital medicine program in optimizing opioid pain control in cancer patients (SWOG S1916). (2020) (0)
- Long-term effect estimation when combining clinical trial and observational follow-up datasets (2022) (0)
- Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic Status-Reply. (2021) (0)
- Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). (2023) (0)
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Metastatic Prostate Cancer Patients (2016) (0)
- Older patient participation in SWOG lung cancer trials: Comparative analysis from 1993 to 2008. (2012) (0)
- Response: Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group (2010) (0)
- 1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial (2021) (0)
- Reply to T.P. Houston et al. (2018) (0)
- SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial. (2015) (0)
- Abstract P6-12-09: Association between cardiovascular risk factors and cardiac events among breast cancer patients enrolled in SWOG clinical trials (2018) (0)
- Abstract A44: Association between BMI at treatment initiation and cancer survival across multiple SWOG trials (2015) (0)
- CL4 MINIMAL CLINICALLY IMPORTANT DIFFERENCE: HOW INTERNATIONAL PATIENTS VIEW PAIN, DISTRESS AND TREATMENT OUTCOMES (2019) (0)
- Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481). (2022) (0)
- Feasibility of a patient-centered method to determine meaningful change in pain intensity on a survey of patients with a history of cancer (2022) (0)
- Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer (2023) (0)
- Capacity to provide specialized care for older adults in community oncology practices: Results of the NCI Community Oncology Research Program (NCORP) Landscape survey. (2019) (0)
- Economic Evaluations in NCI-sponsored Network Cancer Clinical Trials (2021) (0)
- The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. (2019) (0)
- Reply to L. Gianni et al. (2015) (0)
- Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I. (2023) (0)
- Erratum: Chemoprevention of prostate cancer with finasteride: An intergroup trial (Cancer Investigation 13 (Suppl 1): 43 (36), 1995) (1996) (0)
- How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? (2017) (0)
- The association of patient fatigue and outcomes in advanced cancer: An analysis of four SWOG treatment trials. (2020) (0)
- Abstract PD6-04: PD6-04 Baseline Insurance and Unplanned Emergency Room Use and Hospitalizations Among Elderly Breast Cancer Patients Participating in Clinical Trials (2023) (0)
- Incorrect Affiliations and Updated Supplement. (2016) (0)
- Beyond patient-level barriers: Evaluation of rural residency and area-level deprivation and clinical trial (CT) participation. (2020) (0)
- Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma (2014) (0)
- Decreasing Clinical Trial Participation Barriers (2019) (0)
- Abstract P1-11-04: Association between body mass index (BMI) and response to duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) (2019) (0)
- Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-Related Cancers, 1986 to 2016 (2022) (0)
- Title Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients Permalink (0)
- Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions. (2019) (0)
- Title Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer : SWOG S 9630 (2016) (0)
- Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221) (2018) (0)
- Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms (2021) (0)
- Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non- Small-Cell Lung Cancer (2008) (0)
- Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). (2022) (0)
- Error in Article End Matter. (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joseph M Unger?
Joseph M Unger is affiliated with the following schools:
